Printer Friendly

Veteran Pharmaceutical Executive Joins AerovectRx Corp. Board.

ATLANTA -- AerovectRx Corporation, developer of new unit dose aerosol drug delivery technology, today announced that Jonathan Mow has joined the company's board of directors. Mr. Mow has extensive experience in pharmaceutical marketing and business development, with his last two companies focusing on the development and commercialization of aerosol drugs.

"I am very please that Jonathan has joined our board, bringing his wealth of aerosol drug industry knowledge," said Matthew H.J. Kim, J.D., founder and CEO of AerovectRx. "He has been an integral part of creating and growing two highly successful aerosol therapy companies that together were acquired for more than one billion dollars."

"The AerovectRx team has developed a technology platform that represents a tremendous opportunity in the growing aerosol delivery industry," said Mr. Mow. "I believe that the unique AerovectRx platform technology will serve an important need that is not currently being addressed in the aerosol market - disposable, unit-dose cartridges that can be used to efficiently deliver high-value medications."

As co-founder of Corus Pharma, Mr. Mow was an integral member of the management team that positioned the company's aerosol drug pipeline to be acquired for approximately $420 million by Gilead Sciences in 2006. He also was an executive with the respiratory therapeutic company PathoGenesis Corporation which was acquired by Chiron for approximately $700 million in 2000. Mr. Mow previously worked in various strategic planning and marketing positions at Bristol-Myers Squibb, Lederle/Wyeth International and Syntex Laboratories.

About AerovectRx --

AerovectRx Corporation is an aerosol therapeutic company providing effective and dosage-controlled drug delivery using the respiratory system as the gateway for better health. Products under development by AerovectRx are designed to deliver a wide variety of therapies through multiple-use mass immunization as well as personal-use nebulizers. Potential targeted therapeutic candidates for the AerovectRx technology include treatments for asthma, cystic fibrosis, pulmonary hypertension, chronic obstructive pulmonary disease (COPD), diabetes, pain management, and for delivery of vaccines and anti-viral drugs. For more information, visit
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Feb 2, 2007
Previous Article:DigitalPost Interactive Announces It Will Become Publicly Traded under the Symbol DGLP.OB.
Next Article:Finance Concepts Are Covered In a Common Sense Manner and the Use of Mathematical Jargon Is Minimized Inside Modern Financial Markets: Prices,...

Related Articles
Chubb Corp.
People in insurance.
Emerging Cardiovascular, Orthopedics/Spine, Stroke, Drug Delivery, Pharma, Diagnostics and Diabetes Companies Among the 50 Presenters at Medtech...
AerovectRx Corp. to Present Latest Drug Delivery Innovations at Medtech Insight's ``Investment In Innovation'' West Conference.
AerovectRx Corp. Receives FDA 510(k) Clearance for the First Nebulizer Drug Delivery System with Disposable Medication Cartridge; AeroCell(TM)...
AerovectRx Corp. to Present Latest in Nebulizer Drug Delivery Technology at In3 Medical Device Summit; FDA 510(k) Clearance Recently Granted for...
AerovectRx Corp. Announces Initial Funding to Commercialize New Inhaled Drug Delivery Technology; Technology Developed at U.S. CDC Targets $12...

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters